It is obvious our firm, specifically our healthcare segment, has the opportunity to offer substantial growth with the elimination of a particular inefficiency within our business model. We must address the issue of reducing the length of time for conducting clinical trials for our new prescription drugs. Although this component is a small portion of our current business relative to our other business segments (a component of our health care division which is 11% of our overall business) it offers a sustainable area of improvement. Even though our prescription drug business is considerably smaller than other true pharma companies, it's of utmost importance as it comprises the largest segment of growth for our organization since 1999. It is estimated that we lose out on approximately $1 million in lost sales each day the prescription drug that is going through clinical trials is not on the market. There is obviously a significant amount of value as it applies to our future and sustainable growth in shortening the length of time that it takes to complete our clinical trials. A viable solution to be considered for this issue is implementing Electronic Data Capture instead of the current paper-based system that we utilize in our clinical trials. An assessment of the benefits and risks is provided below.
A number of positive benefits have been seen from the initial research of web-enabled EDC for shortening the length of time of our clinical trials. One of the immediate and perhaps the greatest benefits this process offers is that investigative sites enter the data directly into the data management system rather than the information being placed into the system through a series of checkpoints and personnel, eliminating double entry. The records are then immediately available for the us to view. This allowed CRA's to identify data errors immediately rather than identifying the errors later in the process as it was during the current paper-based system. A number of other benefits also became apparent. The software does not have to reside on site for the investigative sites, which reduces the need for us to provide on-site support to them cutting our costs. Moreover, studies have shown us that navigating through the web-based system, produced by the firm Phase Forward, versus proprietary software for PCs is significantly preferred and is associated with a shorter learning curve. The internet is becoming increasingly popular and so is the familiarity with utilizing its capabilities, allowing our sites to have have a greater utilization of the program. Yet another benefit of investing in Phase Forward is that the firm would provide all of the necessary software, peripheral services, development & maintenance, as well as help-desk support for clinical sites, reducing our need for multiple suppliers for each of these processes. Another advantage EDC provided that the existing paper-based model does not, is a more favorable compensation structure for our firm. Majority of the sites require us to provide a significant amount of the payment up-front before the process of data verification fully took place. With EDC, because data verification can occur much quicker and closer to the time of data entry, the payments result in and encourage greater accuracy of the data entry. When considering the data entry costs for a Phase 3 trial, even though the information was directly fed into the system from the sites, CRAs still must make visits, even though less frequently, to the sites for data verification. A significant cost saving could be seen by reducing the number of CRA visits per month to each site ($2,500 per visit with roughly .75 visits/month to over 100 sites). Lastly, we figure the cost of using eCRFs through EDC as compared to paper CRFs result in average a 53% decrease in cost per page ($7.50 average cost/page for paper CRFs, $3.50 average cost/page for eCRFs).
As with all of our investments of this magnitude we must consider the costs and possible negative effects with converting to EDC. The implementation of the web-based system does not come without a substantial investment in the firm Phase Forward noted above. We would pay a per-trail fee ranging from 250,000 to 450,000 to the firm for the software and peripheral services, depending on the size of the trail at hand. It was shown during the set-up phase that the EDC took significantly longer to prepare for the test-sites as compared to the paper based system due to user testing and approval cycles of coding. Another key factor to consider is that although the internet is increasing in popularity and usage, very few sites have the updated equipment and computers to have a reliable and quick access to the internet to fill out the eCRFs. This would result in the investment of purchasing laptops for roughly one-half of our investigator sites at $1,200 each for several hundred sites. Every site, whether it has acceptable computing capabilities or not, needs an assessment of those capabilities, costing roughly $400 per site as well as the help desk support resulting in another investment of $50 per site. A lesser issue to consider is the blurring of the roles and responsibilities of our CRAs and CDMs as a result of the new system. This could cause confusion in terms of the reporting structure and possible lay-offs. Lastly, in initial studies we have encountered relatively low levels of discomfort from our investigative sites with switching to EDC. Numerous practices have become very comfortable with the recording of data by hand as well as the ease of accessing recorded information physically rather than switching through various web-pages.
There are two other possible solutions that have also come to my attention that would be pertinent to consider and have the consulting team weigh in on. These options include simply improving our current paper-based system and digital imaging. Although the due diligence on these two options are not as thorough as the EDC option, it appears these two options appear to be very costly investments. Upgrading our paper-based system would likely entail utilizing express shipments for the paper CRFs or increasing the staff needed to verify the data. It is important to note, however, because this system is already in place the learning curve and adjustments needed are very minimal. When weighing the cost of investing in these additional resources versus the potential cost-savings and significant improvement in the process it appears this option is not very viable. Digital imaging, which to an extent already exists here at P&G and has shown to be relatively successful, again has a limited ability to have a significant impact on the process improvement. This is due to a number of reasons, but most notably the massive amount of storage space needed to store the images.
My initial assessment of the possible solution to improving and shortening our clinical trial process is investing in electronic data capture. After assessing the benefits and risks, much of which is stated above, I believe EDC provides the greatest ability to significantly improve the process at hand. This option allows us to set an industry standard, and I believe create a competitive advantage as the traditional pharma companies are showing a lack of interest in investing in this capability.
I look forward to the meeting with the consultants on Tuesday.
Brian Grau
No comments:
Post a Comment